Table 2.

Antiretroviral resistance in PrEP trials demonstrating efficacy of PrEP for HIV prevention

	# of HIV seroconverters assigned FTC/TDF or TDF PrEP with HIV resistance		Comparison: # of HIV infections averted in the PrEP trial (# of infections in placebo arm minus # of infections in FTC/TDF PrEP arm)
	Individuals with seronegative acute HIV infection at enrollment	Individuals who acquired HIV after enrollment
iPrEx	2/2	0/36	28
Partners PrEP	2/8	0/30	74
TDF2	1/1	0/10	16

Footnote: In iPrEx, the 2 subjects with seronegative acute HIV infection at the time of PrEP initiation both developed M184I/V mutations, conferring resistance to FTC. In Partners PrEP, of 8 subjects with seronegative acute HIV infection at the time of PrEP initiation, 2 developed antiretroviral resistance: one K65R substitution (conferring resistance to TDF) and one M184V substitution. In TDF2, 1 subject, also with seronegative acute HIV infection at the time of randomization to the FTC/TDF PrEP arm, developed both the K65R and M184V substitutions.